Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 51 to 100 of 1904

TitleReference numberPublishedLast updated
Selective internal radiation therapies for treating hepatocellular carcinomaTA688
Minimally invasive percutaneous surgical techniques with internal fixation for correcting hallux valgusIPG789
Tafamidis for treating transthyretin amyloidosis with cardiomyopathyTA984
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)TA982
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinomaTA983
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutationTA979
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal)TA980
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA976
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and overTA977
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)TA978
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)TA972
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndromeHST31
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosisTA127
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosisTA312
Cladribine for treating relapsing–remitting multiple sclerosisTA616
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusionTA283
Ranibizumab and pegaptanib for the treatment of age-related macular degenerationTA155
Ranibizumab for treating choroidal neovascularisation associated with pathological myopiaTA298
Selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liverIPG786
Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetesIPG787
Image-guided percutaneous laser ablation for primary and secondary liver tumoursIPG788
Atogepant for preventing migraineTA973
Selinexor with bortezomib and dexamethasone for previously treated multiple myelomaTA974
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and underTA975
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancerDG58
Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatmentsTA970
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19TA971
COVID-19 rapid guideline: managing COVID-19NG191
Artificial intelligence (AI)-derived software to help clinical decision making in strokeDG57
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and overTA967
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphomaTA540
Digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD: early value assessmentHTE18
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal)TA969
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA968
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)TA966
Lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedemaIPG785
Cabozantinib with nivolumab for untreated advanced renal cell carcinomaTA964
Twin and triplet pregnancyNG137
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA963
Kurin Lock for blood culture collectionMTG77
GaitSmart rehabilitation exercise programme for gait and mobility issuesMTG78
Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancerIPG784
Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal)TA961
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapyTA962
Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal)TA965
Ritlecitinib for treating severe alopecia areata in people 12 years and overTA958
Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosisTA959
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal)TA960
Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessmentHTE17
Ovarian cancer: identifying and managing familial and genetic riskNG241

Results per page

  1. 10
  2. 25
  3. 50
  4. All